INAHTA Briefs

Issue 2007/92

*Title* **Value of Extra-Cranial Stereotactic Radiotherapy**

*Agency* **HAS, Haute Autorité de Santé/French National Authority for Health**
2, avenue du Stade de France, FR-93218 Saint-Denis La Plaine Cedex, France;
Tel: +33 1 55 93 71 97, Fax: +33 1 55 93 74 35; contact.seap@has-sante.fr, www.has-sante.fr

*Reference* December 2006.
www.has-sante.fr/portail/display.jsp?id=c_490533

## Aim

To assess the clinical value of extracranial stereotactic radiotherapy (ESR) to advise French National Health Insurance (NHI) on reimbursement.

## Conclusions and results

According to the 42 selected studies (11 prospective, 31 retrospective):

1. *spinal and paraspinal tumors* (15 studies, 467 patients, median followup 8 to 25 months): pain was decreased in 25% to 100% of patients (8 studies), there were fewer symptoms in 42% to 100% of patients (4 studies), and the local control rate was 87% to 100% (7 studies). No toxicity was observed (9 studies).
2. *bronchopulmonary tumors* (16 studies, 659 patients, median followup 8 to 36 months): the overall control rate was 72% to 100% (13 studies), the 1-year actuarial control rate was 76% to 100% (6 studies), and the 1-year survival rate was 48% to 100% (8 studies). Grade ≥3 complications were observed in 0% to 16% of patients (14 studies).
3. *hepatic tumors* (4 studies, 109 patients; median followup 7 to 12 months): the local control rate was 72% to 95%. No grade 3 toxicity was observed.

The working group also discussed further indications.

## Recommendations

The opinion of HAS (French National Authority for Health) is that NHI should reimburse ESR for spinal tumors, primary T1, T2, N0, M0 bronchopulmonary tumors, and slow-growing bronchopulmonary metastases when the primary tumor is under control. It advised conditional coverage of ESR for hepatic tumors.

## Methods

We reviewed published data on the safety and efficacy of ESR and its contribution to treatment strategy. The review was discussed by an 11-member multidisciplinary working group before submission to the HAS Committee for Assessment of Medical and Surgical Procedures.

## Further research/reviews required

The following are required:

- long-term followup
- further information on the type, volume, and topography of the tumor
- information on therapeutic use compared to other treatments
- health economic assessment in France
- confirmation of the safety and efficacy in indications with conditional coverage.

Written by Céline Moty-Monnereau, HAS, France

ISSN 1654-501X